As of 2026-03-30, 辉瑞的氨曲南/阿维巴坦复方制剂's data on the DeepSeek platform in the 抗生素 category shows: The overall mention rate is 0.00%, above the industry average by 0.0 percentage points, showing notable performance. The first mention rate is only 0.00%, it is recommended to enhance first-position exposure in AI model responses. Negative mention rate (0.00%) has exceeded positive (0.00%), it is recommended to immediately initiate reputation repair. AIGeo recommends combining the above data to formulate targeted brand monitoring strategies to further enhance brand visibility and reputation in the AI search ecosystem.
辉瑞的氨曲南/阿维巴坦复方制剂's Mention Rate is 0.00%, lower than 0.6% of competitors
辉瑞的氨曲南/阿维巴坦复方制剂's First Mention is 0.00%, lower than 0.9% of competitors
辉瑞的氨曲南/阿维巴坦复方制剂's Preferred Rate is 0.00%, lower than 100.0% of competitors
辉瑞的氨曲南/阿维巴坦复方制剂's Positive Rate is 0.00%, lower than 8.9% of competitors
辉瑞的氨曲南/阿维巴坦复方制剂's Negative Rate is 0.00%, higher than 96.3% of competitors
| Competitor | Mention Rate | First Mention | Preferred Rate | Positive Rate | Negative Rate | Actions |
|---|---|---|---|---|---|---|
| 辉辉瑞的氨曲南/阿维巴坦复方制剂 (Current Brand) | 0% | 0% | 0% | 0% | 0% | View Details |
